Frontiers in Health Sciences
Frontiers in Health Sciences is a seminar series organized by the Faculty of Health Sciences doctoral programmes and targeted to researchers, teachers, and students. The seminars are open for everyone interested. Welcome!
A warm welcome to Frontiers in Health Sciences seminar on Thursday 23 January 2025.
Speaker: Prof. Nanna Fyhrquist, Karolinska Institutet
More information available later.
A warm welcome to Frontiers in Health Sciences seminar on Monday 16 December 2024
Speaker: Prof. Hanna Mikkola, UCLA
More information available later.
Frontiers in Health Sciences seminar
hosted by UEF Metabolic Diseases Research Community
A warm welcome to Frontiers in Health Sciences seminar on Wednesday 20 November 2024 at 16:00 in Zoom.
Topic: Integrating single cell omics data with biobank data to identify genes and biomarkers for cardiometabolic disorders
Speaker: Professor Päivi Pajukanta, MD, PhD from UCLA
“I am Päivi Pajukanta, MD, PhD, Professor of Human Genetics, and recipient of The Diller-von Furstenberg Family Endowed Chair in Precision Clinical Genomics in the David Geffen School of Medicine at UCLA. My research group is using integrative genomics approaches on multilayer genomics data, including single cell omics data, to identify cell-type-specific mechanisms underlying obesity and related cardiovascular and metabolic disorders, such as type 2 diabetes (T2D), dyslipidemia, and metabolic dysfunction-associated steatotic liver disease (MASLD). I am especially interested in 1) genomic studies of the admixed Mexican population that has been underrepresented in genomic studies despite their high predisposition to obesity, T2D, dyslipidemias, and MASLD; 2) development of computational approaches for complex traits; and 3) utilizing single cell and bulk level RNA-sequencing and ATAC-sequencing approaches to study gene-environment interactions contributing to cardiovascular and metabolic traits.”
Website: https://bioscience.ucla.edu/people/paivi-pajukanta/
Lab website: https://pajukantalab.dgsom.ucla.edu/
The seminar is organized by the UEF Faculty of Health Sciences and hosted by UEF Metabolic Diseases Research Community.The event is open to everyone interested!
Welcome!
Frontiers in Health Sciences seminar Päivi Pajukanta 20112024
A warm welcome to Frontiers in Health Sciences seminar on Thursday 24 October 2024 at 15:00 in BT1 3208 (Bioteknia) and Teams.
Topic: Looking at neurodevelopmental disorders through the lens of evolution: a role for autophagy
Speaker: Prof. Nael Nadif Kasri
I am a neurobiologist with extensive expertise in synaptic plasticity, focusing on both functional and structural aspects. My training integrates electrophysiology, imaging, and molecular biology, applied in both cellular and animal models. After completing my postdoctoral fellowship at Cold Spring Harbor Laboratory (supported by a Human Frontiers Science Program Fellowship), I established my independent research group in 2011 at Radboud University Medical Center in Nijmegen, the Netherlands, within the Department of Human Genetics.
My research aims to uncover new neurobiological mechanisms underlying neurodevelopmental disorders (NDDs), including intellectual disabilities, autism spectrum disorder, and epilepsy, by investigating disrupted genetic and epigenetic networks. My team employs a multi-disciplinary approach combining functional genomics with molecular and cellular neurobiology, such as the generation and characterization of induced pluripotent stem cell (iPSC)-derived human neural cells and mouse models. Our work is focused on integrating fundamental neurobiological research with clinical applications and personalized medicine. Notably, we have developed strong expertise in generating patient-derived neural lineages and analyzing their neurophysiological properties at both single-cell and network levels using multi-electrode array (MEA) technology, positioning us as leaders in this emerging field.
I have played key roles in numerous national and international research initiatives, including serving as the scientific coordinator of the ZonMW PSIDER program BRAINmodel, and contributing to projects such as the Simons Foundation award, ERANET-Neuron consortium DECODE!, EU-Horizon RIA-SIMPATHIC, EU Marie Curie ITN Scils, E-Rare IMPACT, and EJP-Rare Disorders SCN1A-UP!. In addition, I am the founder and organizer of the annual Dutch Neurodevelopmental Disorders Day and serve on the scientific advisory boards of the Koolen-de Vries Foundation, iDefine, and EpilepsieNL. I also coordinate the Brain Research Theme within the Netherlands Institute for Human Organ and Disease Model Technologies (hDMT).
This diverse array of activities underscores my commitment to advancing both fundamental neurobiological understanding and its translation into clinical applications.
http://www.nadifkasri-lab.com/Home.html
Looking at neurodevelopmental disorders through the lens of evolution: a role for autophagy
Neoteny, the retention of juvenile traits into adulthood, is a defining feature of human brain development and is believed to play a crucial role in shaping the cognitive and behavioral traits that distinguish our species. While the overall sequence of neurodevelopment is largely conserved across mammals, humans display a uniquely extended maturation process, enabling prolonged brain growth and enhanced neural plasticity. Recent research has highlighted the importance of human-specific genetic modifications, such as single nucleotide variants (SNVs), in driving these developmental changes.
In this seminar, I will present our research on a sapiens-specific SNV located in a regulatory region of a gene linked to neurodevelopmental disorders. Using CRISPR/Cas9 technology, we generated isogenic induced pluripotent stem cell (iPSC) lines carrying either the ancestral SNV or disease-causing mutations. Through a series of detailed cell biological and electrophysiological experiments in iPSC-derived neurons and brain organoids, we explored the functional impact of these mutations on neuronal development. Our findings highlight the role of autolysosomal function in brain evolution and development, revealing significant changes in the pace of neuronal maturation. This work deepens our understanding of the genetic and cellular mechanisms that underpin the unique neurodevelopmental trajectory of modern humans.
The seminar is organized by the UEF Faculty of Health Sciences and the event is open to everyone interested.
Welcome!
Frontiers in Health Sciences seminar
organized together with UEF Metabolic Diseases Research Community
A warm welcome to Frontiers in Health Sciences seminar on Wednesday 11 September 2024 at 15:00 in SN201 (Snellmania).
Topic: Towards better brain health with human cellular models – from molecular signatures to function
Speaker: Assistant Professor Helena Kilpinen
Dr. Helena Kilpinen is an assistant professor in genome biology at the Helsinki Institute of Life Science (HiLIFE) and a research group leader at the Institute for Molecular Medicine (FIMM) and Neuroscience Center at the Unversity of Helsinki, Finland. Helena received her PhD from the University of Helsinki in 2011 where she studied the genetic mechanisms underlying autism spectrum disorders. For her postdoctoral training, she transitioned to functional genomics, studying how DNA sequence variation influences different levels of gene regulation in human cells, first at the University of Geneva, Switzerland, and then at the European Bioinformatics Institute (EMBL-EBI) in Cambridge, UK. Helena started her research group in 2016, jointly at the UCL Great Ormond Street Institute of Child Health in London and the Wellcome Sanger Institute in Cambridge, UK. Helena’s group moved to the University of Helsinki in June 2020. Her group studies how genetic variation causes variability in cellular phenotypes, in particular during human neurodevelopment, and contributes to differential susceptibility to diseases, both common and rare.
https://kilpinenlab.org/
Towards better brain health with human cellular models – from molecular signatures to function
Induced pluripotent stem cell (iPSC) -based culture systems have led to a major shift in how we perform and think about human disease modeling, particularly in the context of disorders with a developmental origin. For example, human iPSC-derived neurons and glia have revolutionized the study of brain-related disorders, which previously relied heavily on animal models and post-mortem tissue. However, a significant bottleneck in the field lies in the scalability of iPSC-based experiments, as most current studies are underpowered to detect disease-relevant cellular phenotypes. Further, while genomic technologies, such as single cell RNA-sequencing, are essential in characterising the full spectrum of cell types generated in vitro, gene expression levels alone do not comprehensively reflect changes in cellular function and the biological processes that ultimately drive disease pathophysiology, highlighting the need to measure additional cellular phenotypes. To this end, I will discuss some of the recent efforts in my group to scale up iPSC studies and to understand phenotypic variability in iPSC-derived neuronal cells.
The seminar is organized by the UEF Faculty of Health Sciences together with UEF Metabolic Diseases Research Community. Coffee is served before the seminar in front of the seminar room
Frontiers in Health Sciences seminar
A warm welcome to Frontiers in Health Sciences seminar on Thursday 29 August 2024 at 15:00 in SN200 (Snellmania).
Topic: Drug target discovery using novel single-cell and spatial technologies
Speaker: Sikander Hayat, PhD
Dr. Sikander Hayat is a computer scientist turned computational biologist. He works at the medical hospital in Aachen, Germany, where he aims to bridge gaps between medical, biology and computer science topics. He has a small team of computational biologists that focuses on single-cell, spatial and machine learning to identify novel disease targets using human data. He moved back to Academia after working at Bayer for 5 years and has led and published several projects on biomedical data interpretation in Covid (Schreibing et al. 2022), Cardiac (Kuppe et al., 2022), and renal diseases (Hoeft et al. 2023; Xu et al. 2022). His work has also led to the creation of a spin-off startup – Sequantrix GmbH that aims to find novel drug targets for fibrosis using AI and single-cell omics data.
Frontiers is Health Sciences_07052024_Reinier Boon
Frontiers in Health Sciences seminar
A warm welcome to Frontiers in Health Sciences seminar on Tuesday 7th of May 2024 at 12:30-13:30 in TTA, Tietoteknia.
Topic: How endothelial cells and non-coding RNAs regulate cardiac aging
Speaker: Professor Reinier Boon
Since 2019 Reinier Boon is a professor at the Amsterdam UMC and at the Goethe University in Frankfurt. Reinier received his PhD degree with honors in 2008 from the Academic Medical Center of the University of Amsterdam. After his post-doc project in the Institute for Cardiovascular Regeneration in Frankfurt, Germany, Dr. Boon continued there as a junior group leader. He received multiple awards for his work on the role of small and long non-coding RNAs in aging of the cardiovascular system, for instance the Outstanding Achievement Award of the European Society of Cardiology in 2019. Dr. Boon’s research is mainly funded by the German Center for Cardiovascular Research (DZHK), the European Research Council (Consolidator grant), the Dutch Heart Foundation (DHF) and the European Union (Horizon 2020). Current research is focused on non-coding RNA and aging of the cardiovascular system, in particular in the context of heart failure.
The seminar is organized by the UEF Faculty of Health Sciences, and the event is open to everyone interested.
Welcome!
Frontiers in Health Sciences seminar
A warm welcome to Frontiers in Health Sciences seminar on Thursday 8th of February 2024 at 15:00-16:00 in CA102, Canthia and in Teams.
Topic: Use of real word data for decision making on medicines
Speaker: Prof. Olaf Klungel, Utrecht University
Olaf Klungel is professor of pharmacoepidemiologic methods at Utrecht University, Utrecht, the Netherlands. He is chair of the division of Pharmacoepidemiology & Clinical Pharmacology and scientific director of the Utrecht Institute for Pharmaceutical Sciences. He is also adjunct professor of Pharmacoepidemiology at the University of Southern Denmark in Odense. He was trained as a pharmacist and epidemiologist. His main research area is the development, improvement and evaluation of innovative methods of observational drug research. Main applications are in the post-registration phase of drug development.Prof. Klungel teaches pharmacoepidemiology and pharmacotherapy to medical and pharmacy students. He is (co-)author of over 350 papers in peer reviewed journals, book chapters and research reports.
Frontiers in Health Sciences seminar
A warm welcome to Frontiers in Health Sciences seminar on Monday 4th of December 2023 at 15:00-16:15 in SN200, Snellmania (Kuopio Campus) and in Teams.
Topic: Eliminating the seeds of relapse – targeting residual disease following targeted therapy
Speaker: Kari Kurppa, University of Turku
The laboratory of Dr. Kurppa aims to understand the means cancer cells use to develop resistance to cancer therapies. The laboratoy’s special focus are the mechanisms that enable the establishment of residual disease, or govern the maintenance of residual tumors following targeted cancer therapy. The overarching goal of Dr. Kurppa’s research is to develop rational combination strategies that will extend the long-term efficacy of clinically used cancer therapies.
https://sites.utu.fi/kurppalab/
This seminar is organized in collaboration with UEF CANCER Research community
Frontiers in Health Sciences seminar
A warm welcome to Frontiers in Health Sciences seminar on Thursday 28th of September 2023 at 15-16 in Teams.
Topic: The return of the lesion. Lessons from serendipity and perseverance.
Speaker: Juho Joutsa, University of Turku
Juho Joutsa, MD, PhD graduated from University of Turku and completed postdoctoral training at Massachusetts General Hospital and Harvard Medical School. Currently, he is professor of neurology at University of Turku and chief neurologist at Turku University Hospital. He leads Brain Stimulation and Neuroimaging laboratory (www.turkubrainlab.fi) and acts as the chair of Turku Brain and Mind Center.
Prof. Joutsa’s lab’s research work focuses on investigating the neurobiological mechanisms of brain disorders and aims to facilitate development of new treatment options. Joutsa is interested in a wide spectrum of brain disorders but especially neurological movement disorders and addictions. He uses a multimodal approach, combining brain lesions, state-of-the-art brain imaging methods (MRI, PET, SPECT) and brain stimulation techniques (TMS, DBS).
***
Frontiers in Health Sciences seminar
A warm welcome to Frontiers in Health Sciences seminar on Thursday 7th of September 2023 at 10:00-11:00 in Teams.
Topic: Making sense of antisense transcription in the failing heart – mechanistic insights and therapeutic opportunities
Speaker: Olof Gidlöf, Lund University
Heart failure represents the end-stage of all heart disease and is a leading cause of mortality and hospitalization in developed countries. Therapies aimed at improving cardiac mechanical function and neurohormonal control in heart failure remains an unmet clinical need. Natural antisense transcripts (NATs), i.e., non-coding RNAs transcribed from the opposite strand of a protein-coding gene are a common feature throughout the human genome. Their roles as cis-acting transcriptional and post-transcriptional regulators means that NATs could constitute specific and effective targets for RNA-based therapies. In this seminar, recent data from the Gidlöf lab revealing new insights into the biology and therapeutic potential of cardiac NATs will be disseminated.
Olof Gidlöf is associate professor in experimental cardiology and principal investigator of the Cardiovascular Epigenetics unit at Lund University. OG has a background studying the role of non-coding RNA and epigenetics in cardiovascular disease at Lund University, University of Miami and the Scripps Research Institute. Currently, OG’s research is mainly focused on molecular and translational studies of heart failure, with the aim of identifying targets for RNA-based therapies.